GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » FCF Yield %

Ocugen (Ocugen) FCF Yield % : -21.19 (As of May. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Ocugen's Trailing 12-Month Free Cash Flow is $-72.53 Mil, and Market Cap is $342.25 Mil. Therefore, Ocugen's FCF Yield % for today is -21.19%.

The historical rank and industry rank for Ocugen's FCF Yield % or its related term are showing as below:

OCGN' s FCF Yield % Range Over the Past 10 Years
Min: -21802.86   Med: -35.49   Max: -0.67
Current: -21.19


During the past 12 years, the highest FCF Yield % of Ocugen was -0.67%. The lowest was -21802.86%. And the median was -35.49%.

OCGN's FCF Yield % is ranked worse than
59.5% of 1553 companies
in the Biotechnology industry
Industry Median: -14.39 vs OCGN: -21.19

Ocugen's FCF Margin % for the quarter that ended in Dec. 2023 was -232.34%.


Ocugen FCF Yield % Historical Data

The historical data trend for Ocugen's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen FCF Yield % Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -61.84 -4.46 -5.39 -22.40 -49.16

Ocugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.30 -41.11 -61.98 -66.55 -38.02

Competitive Comparison of Ocugen's FCF Yield %

For the Biotechnology subindustry, Ocugen's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Ocugen's FCF Yield % falls into.



Ocugen FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Ocugen's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-72.53 / 147.526025
=-49.16%

Ocugen's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-14.024 * 4 / 147.526025
=-38.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocugen FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Ocugen FCF Yield % Related Terms

Thank you for viewing the detailed overview of Ocugen's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (Ocugen) Business Description

Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Executives
Junge Zhang director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu officer: CFO/CBO 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri director, officer: Chief Executive Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay officer: Chief Scientific Officer C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar director 375 PHEASANT RUN, NEWTOWN PA 18940
Kirsten Castillo director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Uday Kompella director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Marna C Whittington director 2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo officer: CAO/SVP, Finance C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian officer: Chief Financial Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti director C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355

Ocugen (Ocugen) Headlines

From GuruFocus

Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023

By sperokesalga sperokesalga 04-11-2023

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

By sperokesalga sperokesalga 06-09-2023

Ocugen to Present at BIO International Convention 2023

By sperokesalga sperokesalga 05-23-2023

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

By sperokesalga sperokesalga 05-23-2023